- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04282694
PRogetto Salute Parma (PSP)
PRogetto Salute Parma: PRevenzione Primaria e Secondaria Del Danno da Fumo
This project from the University Hospital of Parma (AOUPR) aims to verify the feasibility of a prevention program in our district, relying on advanced technological resources and highly experienced team in lung cancer early diagnosis, in order to identify useful elements towards the applicability of such a prevention program on a large scale (regional, national).
Uncontrolled, monocentric experimental study with dynamic enrollment and prospective data collection, aimed at implementing a prevention program based on scientific evidence. This study is set to verify the applicability and feasibility of a lung cancer prevention program in a real context, including a preliminary evaluation at the smoking cessation clinic and a LDCT assessment with subsequent LDCT follow-up for participants who show indeterminate findings at the first LDCT (LDCT baseline) exam.
The main objective of the study is to verify the feasibility of a lung cancer prevention program according to internationally validated scientific methods.
Secondary objectives:
- To evaluate the use of local smoking cessation clinics and their effects in terms of smoking cessation (primary prevention)
- To evaluate the outcomes of the program in terms of number of patients with early (presymptomatic) lung cancer treated with minimally invasive surgery (secondary prevention)
- To evaluate the number of false positives and their diagnostic work-up (PET-CT, CT-guided biopsy, bronchoscopy)
Primary endpoint:
- Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
Secondary endpoints:
- To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
- To measure the variation in smoking habits in enrolled smokers
- To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site
- To measure the consequent demand for further diagnostic investigations and treatment
- To measure the number of false positives
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program.
Inclusion criteria
- Age between 50 and 75 years
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Exclusion criteria
• Personal history of cancer within the prior 5 years
We expect to recruit around 500 people in 1 year. This sample size is considered adequate based on the available resources, both human and economic.
After closing and adjusting the database and before data analysis, a document called Statistical Analysis Plan (SAP) will be drawn up. It will consist of the following paragraphs:
- Statistical methods planned in the study protocol;
- Size of the sample;
- Management of missing data;
- Evaluation of the endpoints;
- Statistical models that will be applied in the analysis. The socio-demographic characteristics of the enrolled subjects, the adopted organizational methods and the effects of the prevention program (endpoints) will be analyzed and described using tables and figures.
The project "PRogetto Salute Parma: Primary and secondary prevention of smoking-related lung cancer" will be started once approved by the institutional Ethics Committee and authorized by the General Manager. The study is expected to be carried out over 2 years (from the inclusion of the first subject), with an expected period of 1 year for the enrolment and 1 further year for follow-up.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Parma, Italy
- University of Parma
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Equivalent tobacco intoxication of ≥ 15 cigarettes per day for ≥25 years or ≥ 10 cigarettes per day for ≥30 years
- Status of current smoker or ex-smoker for <10 years.
Exclusion Criteria:
- Personal history of cancer within the prior 5 years
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
High risk (former) smokers
Subjects at high risk of lung cancer screened by the medical team of the AOUPR or by GPs to join the prevention program. Inclusion criteria
Exclusion criteria • Personal history of cancer within the prior 5 years |
Early detection of lung cancer by LDCT and smoking cessation counselling
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adherence
Time Frame: 12 months
|
Percentage of enrolled subjects to whom the program was offered within 60 days from the date of enrolment and percentage of those who stop smoking for at least 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Organization model
Time Frame: 18 months
|
To describe the organizational model, human resources employed, difficulties encountered and elements that have favoured its realization
|
18 months
|
Smoking cessation
Time Frame: 24 months
|
To measure the variation in smoking habits in enrolled smokers.
|
24 months
|
Secondary prevention of lung cancer
Time Frame: 24 mesi
|
To describe the effect of annual LDCT on lung cancer diagnosis rates, considering size, shape, histology and site.
|
24 mesi
|
Work up burden
Time Frame: 24 months
|
To measure the demand for further diagnostic investigations and treatment generated by LDCT.
|
24 months
|
False positives
Time Frame: 24 months
|
To measure the number of false positives generated by LDCT
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicola Sverzellati, MD, PhD, University of Parma
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 837/2019/OSS/UNIPR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht UniversityThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on Low-dose computed tomography (LDCT)
-
University Health Network, TorontoActive, not recruiting
-
Cathay General HospitalUnknown
-
Postgraduate Institute of Medical Education and...Completed
-
Wake Forest University Health SciencesLeon Levine FoundationRecruitingLung Neoplasms | Lung CancerUnited States
-
N.N. Petrov National Medical Research Center of...CompletedLung CancerRussian Federation
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States
-
National Cancer Institute (NCI)American College of Radiology Imaging NetworkCompleted
-
Xuzhou Central HospitalCompletedLung Cancer | Lung; NodeChina
-
Xuzhou Central HospitalCompletedLung Cancer, Adenocarcinoma | Lung Inflammatory PseudotumorChina
-
University of CalgaryAlberta Cancer Foundation; Western Canadian Mesothelioma FoundationTerminatedLung Cancer | MesotheliomaCanada